




Atazanavir: Treating HIV/AIDS



Atazanavir is an antiretroviral drug mainly used as a protease inhibitor in combination therapies treating HIV/AIDS.

Drug names throughout patent history

When the initial patent application for Atazanavir was filed, the chemical substance wasn't known as such. Non-proprietary generic names like Atazanavir are only applied to compounds once they have been improved for clinical investigation.

Pre-clinical names		Clinical name		
Chemical name	Inventor name	Manufacturer name	Generic name	Brand name for drug as sold
Heterocyclic azahexane derivatives	CGP-73547, CGP-75355, CGP-75136	BMS-232632	Atazanavir	Reyataz®

Developers' patenting activity


Number of patent filings



The initial patent application was filed in 1995 by Novartis (then Ciba-Geigy), which made a licensing agreement with Bristol-Myers Squibb for further development, manufacturing and clinical trial work.


Overall patenting activity

Number of patent families* (incomplete data after 2008 due to publication lag)




Key aspects of drug development

Number of patent search results



Offices of first filing

Number of patent filings



*A patent family is a set of patent filings made in various countries to protect a single invention.